UK Medical Device Maker Smith & Nephew Ramping Up Production In China Despite Counterfeiting Concerns
This article was originally published in PharmAsia News
Executive Summary
HONG KONG - Counterfeiting concerns and countermeasures remain a top priority for many major healthcare outfits that are establishing or expanding operations in China
You may also be interested in...
Lack Of Globally Accepted Definition of “Counterfeit Drug” Hurts U.S. FDA, Department Of Commerce Drive To Tackle Problem
Efforts by global stakeholders - including national governments, nongovernmental organizations, and drug companies - to curtail counterfeit drug production are hampered by the lack of an agreed-upon definition for "counterfeit.
Counterfeit Drugs Produced In China Still Threaten Chinese, U.S., Global Consumers
BEIJING - Unless China does more to crack down on counterfeiting and contamination in its pharmaceutical industry, the United States could see a repeat of Chinese-made drugs or raw components causing severe adverse reactions in American hospitals, according to a Washington, D.C.-based scholar
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).